Share Name Share Symbol Market Type Share ISIN Share Description
Silence Therapeutics Plc LSE:SLN London Ordinary Share GB00B9GTXM62 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -2.00 -0.45% 438.00 428.00 434.00 446.00 428.00 440.00 58,462 16:35:29
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -20.5 -26.2 - 342

Silence Therapeutics Share Discussion Threads

Showing 50351 to 50374 of 50950 messages
Chat Pages: Latest  2026  2025  2024  2023  2022  2021  2020  2019  2018  2017  2016  2015  Older
DateSubjectAuthorDiscuss
20/8/2018
15:15
We got a lot of mentions in the news this weekend on the back of the ALNY approval. Also had Peel Hunt reiterate its Buy rating a few weeks ago - has anyone read that btw?
frndlyfire
20/8/2018
11:31
Perhaps everyone should leave then!
djnzloop
20/8/2018
08:57
And once again, the shareprice reaction to a sudden departure at the top is to spike...
1gw
20/8/2018
08:53
Another sudden departure. Was she hoping to get the CEO job or was it just job done once the new CEO was in place?
1gw
16/8/2018
18:32
I'm also hoping for that outcome, but clearly there's a risk that the Silence strategy misfires. If Alny believe SLN don't have a reasonable case then they may just play hardball and hope that their greater resources will eventually be enough to force SLN to try to settle for a minimal amount in order to stop the drain on their own resources.
1gw
16/8/2018
17:35
That's also my thinking.
waterloo01
16/8/2018
16:51
Why doesn't ALNY buy SLN? For a company that size it would surely be drop in the ocean, and make all this lawsuit noise go away. What am i missing?
frndlyfire
16/8/2018
07:55
Maybe make my next purchase at 90p?
volsung
10/8/2018
19:57
hTtps://www.statnews.com/2018/08/10/fda-alnylam-rnai-patisiran-onpattro/ Time to pay up!
waterloo01
08/8/2018
16:06
hey @buywell what was the Daily Mail spin? SLN already commented on this in an RNS on the 7th. SLN are now litigating for a potentially increasingly successful use of their IP - doesn't seem like a negative to me as they were already litigating.
djnzloop
08/8/2018
13:19
piece in the Daily Mail today stockwatch didn't read too good, about this On 3 August 2018, Alnylam Pharmaceuticals Inc. ("Alnylam") announced that the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) had granted its RNAi medicine, patisiran, a positive scientific opinion through the Early Access to Medicines Scheme. Further to this decision, Alnylam can provide eligible adults in the UK with access to patisiran before the drug is granted EU marketing authorisation by the European Commission. Grant of the EU marketing authorisation for patisiran is imminent.
buywell3
03/8/2018
13:56
CEO & CSO both quit in June without any real explanation. New CEO appears to have been made unexpectedly available - but does seem to fit the bill with a previous sale experience. I reckon the market is guessing there may be some bad news due perhaps about the pending litigation this December... also it is very frustrating watching them sell their stake in Arrowhead only to watch it soar away - perhaps some contention there??I guess some news flow would help here
djnzloop
03/8/2018
13:15
Chartwise 75p seems possible
buywell3
03/8/2018
13:10
Could anyone tell me what has happened in the last couple of weeks for the share price to have dropped about 40 points,or nearly 25%.
tshirley12
02/8/2018
16:53
htTp://investors.alnylam.com/news-releases/news-release-details/alnylam-pharmaceuticals-reports-second-quarter-2018-financial No mention of SLN but they do have $1.5bn in cash!
waterloo01
31/7/2018
09:35
Hi Callumross,thanks for that info.
tshirley12
30/7/2018
22:11
From what I understand it is all technical stuff so far, such as SLN challenging jurisdiction, and it is not about "winning" as such, rather about successfully defending an action brought by ALNY. Unlike the Portugal case and the UK case to be held in December where SLN is the litigant. Will be many months before all this is cleared up and is probably a distraction from the other news such as the Quark phase 3 trials and the new clinical trials scheduled for the end of the year. Having said that, if they win some of these cases, it will make the current market cap look very cheap and remember that the most recently granted US patents do not form part of the ALNY US action.
callumross
30/7/2018
22:11
From what I understand it is all technical stuff so far, such as SLN challenging jurisdiction, and it is not about "winning" as such, rather about successfully defending an action brought by ALNY. Unlike the Portugal case and the UK case to be held in December where SLN is the litigant. Will be many months before all this is cleared up and is probably a distraction from the other news such as the Quark phase 3 trials and the new clinical trials scheduled for the end of the year. Having said that, if they win some of these cases, it will make the current market cap look very cheap and remember that the most recently granted US patents do not form part of the ALNY US action.
callumross
30/7/2018
18:25
Hi Callumross, have never posted before,but a long time share holder.Checked out your link,to be honest I don't understand all the legal technicalities,Put simply in your opinion are we winning or not.
tshirley12
30/7/2018
15:02
Link to ongoing US Court case; https://www.pacermonitor.com/public/case/24076996/Alnylam_Pharmaceuticals,_Inc_v_Silence_Therapeutics_GmbH_et_al
callumross
18/7/2018
22:29
The results of this could potentially move SLN higher later in the year; "The same molecule QPI-1002 also completed dosing of 594 patients in a pivotal Phase 3 study (QRK306, NCT02610296) for delayed graft function (DGF) following kidney transplantation in January 2018. As in the AKI trial, the company reached agreement with the FDA on the overall Phase 3 trial design with a new innovative primary endpoint for DGF, based on the DGF Phase 2 data (QRK006, NCT00802347). We anticipate receiving the first interpretative results (FIR) in the fourth quarter of 2018."
callumross
11/7/2018
06:21
Good lord, even I remember this Quark trial from many years ago. Anyone remember the details of milestone payments ?
waterloo01
11/7/2018
06:18
Good to see the Phase 3 AKI trial has finally made it to an rns. I was beginning to think they weren't going to bother.
1gw
06/7/2018
13:08
After many years absence I bought a few over the last few days. Doesn't take much to move. My reasoning for buying now is less what SLN are doing (very little over the years) but that the combination of new blood and more particularly Alnylam's trail progress. My 'hope' is that they make SLN disputes go away by buying them out. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis htTps://www.nejm.org/doi/full/10.1056/NEJMoa1716153
waterloo01
Chat Pages: Latest  2026  2025  2024  2023  2022  2021  2020  2019  2018  2017  2016  2015  Older
Your Recent History
LSE
SLN
Silence Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191122 18:00:56